Ac Immune Stock Filter Stocks by Fundamentals
| ACIU Stock | USD 2.45 0.07 2.78% |
AC Immune fundamentals help investors to digest information that contributes to AC Immune's financial success or failures. It also enables traders to predict the movement of ACIU Stock. The fundamental analysis module provides a way to measure AC Immune's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to AC Immune stock.
| Last Reported | Projected for Next Year | ||
| Price To Sales Ratio | 24.06 | 34.98 |
ACIU | Price to Sales |
AC Immune Current Valuation Drivers
We derive many important indicators used in calculating different scores of AC Immune from analyzing AC Immune's financial statements. These drivers represent accounts that assess AC Immune's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of AC Immune's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 582.7M | 327.7M | 339.0M | 157.5M | 356.0M | 601.3M | |
| Enterprise Value | 392.0M | 169.0M | 259.7M | 128.8M | 281.0M | 486.4M |
ACIU Fundamentals
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.18 | ||||
| Operating Margin | (0.24) % | ||||
| Current Valuation | 137.21 M | ||||
| Shares Outstanding | 98.9 M | ||||
| Shares Owned By Insiders | 41.87 % | ||||
| Shares Owned By Institutions | 30.22 % | ||||
| Number Of Shares Shorted | 560.59 K | ||||
| Price To Earning | (16.96) X | ||||
| Price To Book | 1.55 X | ||||
| Price To Sales | 18.31 X | ||||
| Revenue | 14.8 M | ||||
| Gross Profit | (56.4 M) | ||||
| EBITDA | (50.37 M) | ||||
| Net Income | (54.23 M) | ||||
| Cash And Equivalents | 154.15 M | ||||
| Cash Per Share | 1.83 X | ||||
| Total Debt | 3.5 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 13.28 X | ||||
| Book Value Per Share | 1.71 X | ||||
| Cash Flow From Operations | (60.41 M) | ||||
| Short Ratio | 3.18 X | ||||
| Earnings Per Share | (0.70) X | ||||
| Target Price | 10.49 | ||||
| Number Of Employees | 133 | ||||
| Beta | 1.01 | ||||
| Market Capitalization | 249.23 M | ||||
| Total Asset | 182.81 M | ||||
| Retained Earnings | (316.2 M) | ||||
| Working Capital | 111.58 M | ||||
| Current Asset | 160 M | ||||
| Current Liabilities | 11 M | ||||
| Net Asset | 182.81 M |
About AC Immune Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze AC Immune's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AC Immune using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AC Immune based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with AC Immune
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AC Immune position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AC Immune will appreciate offsetting losses from the drop in the long position's value.Moving against ACIU Stock
| 0.68 | EWTX | Edgewise Therapeutics Financial Report 9th of May 2024 | PairCorr |
| 0.67 | MRK | Merck Company Earnings Call Next Week | PairCorr |
| 0.48 | RZLT | Rezolute Trending | PairCorr |
| 0.44 | NVO | Novo Nordisk AS Financial Report 2nd of May 2024 | PairCorr |
| 0.42 | CELC | Celcuity LLC Financial Report 20th of May 2024 | PairCorr |
The ability to find closely correlated positions to AC Immune could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AC Immune when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AC Immune - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AC Immune to buy it.
The correlation of AC Immune is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AC Immune moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AC Immune moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AC Immune can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out AC Immune Piotroski F Score and AC Immune Altman Z Score analysis. For more information on how to buy ACIU Stock please use our How to Invest in AC Immune guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Complementary Tools for ACIU Stock analysis
When running AC Immune's price analysis, check to measure AC Immune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AC Immune is operating at the current time. Most of AC Immune's value examination focuses on studying past and present price action to predict the probability of AC Immune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AC Immune's price. Additionally, you may evaluate how the addition of AC Immune to your portfolios can decrease your overall portfolio volatility.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |
Is AC Immune's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AC Immune. If investors know ACIU will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AC Immune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.70) | Revenue Per Share 0.175 | Quarterly Revenue Growth 14.8 K | Return On Assets (0.18) | Return On Equity (0.33) |
The market value of AC Immune is measured differently than its book value, which is the value of ACIU that is recorded on the company's balance sheet. Investors also form their own opinion of AC Immune's value that differs from its market value or its book value, called intrinsic value, which is AC Immune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AC Immune's market value can be influenced by many factors that don't directly affect AC Immune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AC Immune's value and its price as these two are different measures arrived at by different means. Investors typically determine if AC Immune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AC Immune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.